FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
Express Mail Label Number	Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1646

AZRIA ET AL.

Examiner: Xie, Xiaozhen

INTERNATIONAL APPLICATION NO: PCT/EP2004/008210

FILED: 22 JULY 2004

U.S. APPLICATION NO: 10/565,455

35 USC §371 DATE: 5 APRIL 2006

FOR: USE OF CALCITONIN IN OSTEOARTHRITIS

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed January 20, 2006. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. These references are of record in the instant PCT application PCT/EP2004/008210. At the examiners request, copies are enclosed herewith.

A copy of JP 05345729 and an English abstract were previously submitted to the USPTO. Applicant has placed "JP 05 345729" in the "Foreign Patent Documents" section as requested by the Examiner. JP5345729 is provided with an English Abstract that provides the concise explantaion of the relevance of JP534579.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 101 East Hanover, NJ 07936-1080 (862) 778-9308

Date:

17/2/08

Respectfully submitted,

Leslie**∀**ischer

Attorney for Applicants

Reg. No. 58,393